Meet the 2021 Laureates: Takashi Kadowaki, MD, PhD

虎の門病院院長_門脇孝(白衣)

Roy O. Greep Award for Outstanding Research

Takashi Kadowaki, MD, PhD

 

Adiponectin is an adipocyte hormone that is most abundantly expressed in white adipose tissue. Dr. Kadowaki discovered that adiponectin enhances insulin sensitivity and possesses anti-diabetic actions. He identified and cloned the receptors of adiponectin (AdipoR1 and AdipoR2), both of which are seven-transmembrane receptors. Remarkably, they were found to represent a new family of receptors with their N-terminals inside, and their C-terminals outside of the cells, with the reverse topology of G-protein-coupled receptors (GPCR).

Dr. Kadowaki showed that AdipoR1 activates the AMP kinase pathway and AdipoR2 activates the PPAR pathway, both of which regulate oxidation of glucose and fatty acids and enhance insulin sensitivity. In obese subjects, both adiponectin and AdipoR1/R2 levels are reduced, substantially contributing to the pathophysiology of type 2 diabetes, metabolic syndrome, cardiovascular disease, and reduced longevity.

He was the first to succeed in developing a small-molecule adiponectin receptor agonist (AdipoR Agonist: AdipoRon). Orally administered AdipoRon activates the same signaling pathway as caloric restriction and physical exercise, thereby improving obesity-related diseases as a whole, including type 2 diabetes. This proof of concept for an oral Adiponectin drug has fostered tremendous interest in adiponectin therapeutics, facilitated by his recent elucidation of the three-dimensional structure of adiponectin receptors.

Dr. Kadowaki has also led important genetic and clinical studies that have important impact for understanding, diagnosis and treatment of metabolic disorders. His recent genetics have confirmed the importance of identifying genetic variation and diabetes susceptibility in Asian populations. Dr. Kadowaki’s accomplishments have not only enabled essential understanding of the molecular mechanisms of adiponectin action but have re-invigorated adiponectin-based drug development programs for type 2 diabetes. Collectively, his body of work, broadly focused on insulin action in health and disease, exhibits both a high degree of novelty and immediate translational relevance.

 

 

You may also like

  • Members in the News: Joshua Klopper, MD, Named Veracyte’s Medical Director of Endocrinology

    Endocrine Society member Joshua Klopper, MD, has been appointed medical director of Endocrinology at the genomic diagnostics company Veracyte.  Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to another Society member, Richard T. Kloos, MD, Veracyte’s executive medical director….

  • Movers & Shakers: Lab Relocation During a Pandemic

    Moving is always stressful. Just imagine factoring in social distancing protocols, adhering to California’s earthquake safety standards, and pausing your research to get it done. Joy Y. Wu, MD, PhD, talks to Endocrine News about moving her research lab at Stanford University under less-than-ideal circumstances but she and her team got it done with a…

Find more in